Abstract: In a method for treating a cancer expressing secreted protein acidic and rich in cysteine (SPARC), a composition including an albumin and at least one cysteine bound thereto is administered to a subject in need thereof. The cancer expressing the SPARC may be at least one selected from the group consisting of a brain tumor, melanoma, breast cancer, rectal cancer and stomach cancer.

Abstract: Provided is a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an active ingredient, and a method for preventing, alleviating or treating breast cancer using the composition by inhibiting the activity of polo-like kinase 1 (PlK1).

Abstract: The present invention relates to a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an effective ingredient for prevention or treatment of prostate cancer. THA in the present invention is a main ingredient of Curcuma comosa. The composition of the present invention effectively inhibits the growth of prostate cancer by regulating in particular the activity of polo-like kinase 1 (PLK1) and thus is expected to find useful applications in use in the prevention, alleviation, and treatment of prostate cancer in future.

Abstract: A composition for treatment of a cancer according to an embodiment of the present disclosure expresses secreted protein acidic and rich in cysteine (SPARC). The composition includes an albumin and at least one cysteine bound thereto.

Abstract: The present invention relates to a pharmaceutical composition for prevention or treatment of an allergic disease comprising a mixed extract of two or more selected from the group consisting of Asiasarum root, Platycodon root, and Cinnamomi ramulus as an active ingredient; a method for prevention or treatment of an allergic disease using the pharmaceutical composition; and a health functional food and a feed composition for improvement of an allergic disease. The composition provided in the present invention comprising a mixed extract of two or more selected from the group consisting of Asiasarum root, Platycodon root, and Cinnamomi ramulus as an active ingredient can specifically inhibit the differentiation of Th2 cells and thus can be effectively used as a composition for prevention or treatment of an allergic disease.

Abstract: The present invention relates to a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an effective ingredient for prevention or treatment of prostate cancer. THA in the present invention is a main ingredient of Curcuma comosa. The composition of the present invention effectively inhibits the growth of prostate cancer by regulating in particular the activity of polo-like kinase 1 (PLK1) and thus is expected to find useful applications in use in the prevention, alleviation, and treatment of prostate cancer in future.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis, and more specifically, to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis comprising a gold-containing agent. The pharmaceutical composition of the present invention, by comprising the gold-containing agent as an active ingredient, not only promotes M2-type transformation of macrophages but also inhibits the activation of stellate cells due to the increase of TREM-2 expression, and is thus expected to be effectively used as a pharmaceutical composition, a food composition, etc., for preventing, treating, or ameliorating liver fibrosis or liver cirrhosis. Additionally, gold-containing agents, such as auranofin, sodium aurothiomalate, and aurothioglucose, have long been used for the treatment of a different disease (rheumatoid arthritis), and thus they have an advantage in that they are less likely to cause adverse effects.

Abstract: Provided is a composition comprising 2,4,6-trihydroxyacetophenone (THA) as an active ingredient, and a method for preventing, alleviating or treating breast cancer using the composition by inhibiting the activity of polo-like kinase 1 (PLK1).

Abstract: The present invention relates to a pharmaceutical composition containing a G protein coupled receptor 119 (GPR119) ligand as an effective ingredient for preventing or treating non-alcoholic steatohepatitis. More particularly, it was confirmed that the GPR119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the GPR119 ligand can be useful to treat non-alcoholic steatohepatitis.

Abstract: Provided is a pharmaceutical composition for preventing or treating liver fibrosis, comprising a GPR119 ligand as an active ingredient. The composition comprising the GPR119 ligand as an active ingredient significantly inhibits the expression of collagen I, transforming growth factor ? (TGF?) and ?-smooth muscle actin (?-SMA), thereby inhibiting HSC activation, and also significantly inhibits HSC proliferation. Therefore, the composition may be effectively applied in improvement, prevention, inhibition or treatment of liver fibrosis.

Abstract: Provided are a method for simultaneously detecting fluorescence and Raman signals for multiple fluorescence and Raman signal targets, and a medical imaging device for simultaneously detecting multiple targets using the method. The method includes: injecting at least one marker particle comprising Raman markers and receptors into the body of an animal, which can be a human; irradiating a laser beam onto the body of the animal; and detecting the optical signals emitted by the marker particle after the irradiation of the laser beam separately as fluorescence signals and Raman signals. The simultaneous detection of multiple targets may be performed even without scanning optical signals emitted by the marker particle individually with different optical fibers. As an examination may be performed by injecting surface-enhanced Raman marker particles, weak Raman signals may be augmented so as to obtain a more accurate diagnosis result in real time.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis, and more specifically, to a pharmaceutical composition for preventing or treating liver fibrosis or liver cirrhosis comprising a gold-containing agent. The pharmaceutical composition of the present invention, by comprising the gold-containing agent as an active ingredient, not only promotes M2-type transformation of macrophages but also inhibits the activation of stellate cells due to the increase of TREM-2 expression, and is thus expected to be effectively used as a pharmaceutical composition, a food composition, etc., for preventing, treating, or ameliorating liver fibrosis or liver cirrhosis. Additionally, gold-containing agents, such as auranofin, sodium aurothiomalate, and aurothioglucose, have long been used for the treatment of a different disease (rheumatoid arthritis), and thus they have an advantage in that they are less likely to cause adverse effects.

Abstract: Provided is a pharmaceutical composition for preventing or treating liver fibrosis, comprising a GPR119 ligand as an active ingredient. The composition comprising the GPR119 ligand as an active ingredient significantly inhibits the expression of collagen I, transforming growth factor ? (TGF?) and ?-smooth muscle actin (?-SMA), thereby inhibiting HSC activation, and also significantly inhibits HSC proliferation.

Abstract: Provided are a method for simultaneously detecting fluorescence and Raman signals for multiple fluorescence and Raman signal targets, and a medical imaging device for simultaneously detecting multiple targets using the method. The method includes: injecting at least one marker particle comprising Raman markers and receptors into the body of an animal, which can be a human; irradiating a laser beam onto the body of the animal; and detecting the optical signals emitted by the marker particle after the irradiation of the laser beam separately as fluorescence signals and Raman signals. The simultaneous detection of multiple targets may be performed even without scanning optical signals emitted by the marker particle individually with different optical fibers. As an examination may be performed by injecting surface-enhanced Raman marker particles, weak Raman signals may be augmented so as to obtain a more accurate diagnosis result in real time.

Abstract: The present invention relates to a pharmaceutical composition containing a G protein coupled receptor 119 (GPR119) ligand as an active ingredient for preventing or treating non-alcoholic fatty liver disease. More particularly, it was confirmed that the GPR119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the GPR119 ligand can be useful to treat non-alcoholic fatty liver.

Abstract: Method pertains to a medical imaging device for simultaneously detecting fluorescence and Raman signals for multiple fluorescence and Raman signal targets. The method includes: injecting at least one marker particle including Raman markers and receptors into the body of an animal, which can be a human; irradiating a laser beam onto the body of the animal; and detecting the optical signals emitted by the marker particle after the irradiation of the laser beam separately as fluorescence signals and Raman signals. The simultaneous detection of multiple targets may be performed even without scanning optical signals emitted by the marker particle individually with different optical fibers. As an examination may be performed by injecting surface-enhanced Raman marker particles, into which fluorescent components are introduced, into the body of the animal using a spray or the like, weak Raman signals may be augmented so as to obtain a more accurate diagnosis result in real time.

Abstract: A kit and a composition comprising Herceptin, an antibody binding specifically to HER2, based on detecting Herceptin-sensitive HER2-overexpressing cells are provided for diagnosing cancer. A method of detecting Herceptin-sensitive HER2-overexpressing cells using the same is also provided.

Abstract: A pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis, which comprises 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and dimethyl-4,4?-dimethoxy-5,6,5?,6?-dimethylene dioxybiphenyl-2,2?-dicarboxylate (DDB) as major components, is provided. The ratio of oltipraz and DDB of said composition is preferably 25:0–25, more preferably 5:0.1–5, particularly preferably 5:1. Oltipraz/DDB formulations according to the present invention exhibit surprisingly good effect on the treatment and prevention of liver fibrosis and cirrhosis and are safe drugs that have low toxicity in the human body.

Abstract: The present invention provides a pharmaceutical composition and the use thereof for regeneration of liver tissues to treat cirrhotic liver, the composition including 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) as an active ingredient. The oltipraz composition promotes regeneration of liver tissues in a cirrhotic liver, thereby useful in treating cirrhosis.

Abstract: The present invention provides a pharmaceutical composition and the use thereof for regeneration of liver tissues to treat cirrhotic liver, the composition including 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) as an active ingredient. The oltipraz composition promotes regeneration of liver tissues in a cirrhotic liver, thereby useful in treating cirrhosis.